Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D
Status:
Completed
Trial end date:
2020-04-02
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, active-controlled, single-dose, 3-treatment, 3-period,
3-way crossover, comparative PD and PK inpatient study in adults with T1D. The study
comprises 5 visits: Screening (Visit 1), Treatment Periods (Visits 2 - 4), and Follow-Up
(Visit 5).